Compounds > lenalidomide
Page last updated: 2024-09-05

lenalidomide and thiophenes

lenalidomide has been researched along with thiophenes in 3 studies

Compound Research Comparison

Studies
(lenalidomide)		Trials
(lenalidomide)		Recent Studies (post-2010)
(lenalidomide)		Studies
(thiophenes)		Trials
(thiophenes)		Recent Studies (post-2010) (thiophenes)
3,5327252,85017,0121,9618,038

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Bockman, J; Rice, MC1
Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B1
Jakubowiak, AJ; Johnson, D; Nakamura, Y; Park, JH; Rosebeck, S; Stefka, AT1

Other Studies

3 other study(ies) available for lenalidomide and thiophenes

ArticleYear
Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.
    IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:10

    Topics: Angiogenesis Inhibitors; Benzamides; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cooperative Behavior; Diphenylamine; Drug Industry; Drugs, Investigational; Humans; Lenalidomide; Marketing; Phthalazines; Piperazines; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Stem Cell Factor; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A

2005
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Cancer cell, 2012, Sep-11, Volume: 22, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Lenalidomide; Mice; Mice, SCID; Molecular Sequence Data; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Random Allocation; Thalidomide; Thiophenes; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays

2012
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
    Cancer medicine, 2020, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Female; Humans; Lenalidomide; Leukocytes, Mononuclear; Mice; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Primary Cell Culture; Protein Kinase Inhibitors; Quinolones; Thiophenes; Xenograft Model Antitumor Assays

2020